Szemészet, 2012 (149. évfolyam, 1-4. szám)

2012-03-01 / 1. szám

Retinal vein occlusion

101: 1357.

57. Klein R, Klein BE, Moss SE. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-41.

58. Kohner EM, Pettit JE, Hamilton AM. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J 1976; 1: 550-3.

59. Leizaola-Fernández C, Suárez-Tatá L, Quiroz-Mercado H. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. BMC Ophthalmol Iserial online! 2005; 5: 10. Available at: http://www.biomedcentral.com/ 1471- 2415/5/10, dátum nélk.

60. Loewenstein A, Goldstein M, Winder A. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology 1999; 106: 1817-1820.

61. Majji AB, Janarthanan M, Naduvilath TJ. Significance of refractive status in branch retinal vein occlusion. Retina 1997; 17: 200-4.

62. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of makular edema in retinal vein occlusion: a report of 14 cases. Retina 2004; 24: 348-55.

63. McAllister IL, Gillies ME, Smithies LA. The Central Retinal Vein Bypass Study, a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010; 117: 954-965.

64. McIntosh RL, Rogers SL, Um L, et al. Natural history of central retinal vein occlusion: An evidence-based systematic review. Ophthalmology 2010; 117: 1113-1123.

64a.McIntosh RL, Mohamed Q, Saw SM, Wong TY: Interventions for branch retinal vein occlusion an evidence-based systematic review. Ophthalmology 2007:114: 835-846.

65. McLeod, D. Cilio-retinal arterial circulation in central retinal vein occlusion. Br J Ophthalmol 1975; 59: 486-492.

65a. Mirshahi A, Roohipoor R, Lashay A: Surgical induction of chorioretinal venous anastamosis in ischaemic central retinal vein occlusion: a nonrandomised controlled clinical trial. Br J Ophthalmol. 2005; 89: 64-9.

66. Mitchell R Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-7.

67. Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for Central Retinal Vein Occlusion. An Evidence-Based Systematic Review. Ophthalmology 2007; 114: 507-519.

68. Nagy V, Steiber Z, Takács L, et al. Thrombophilic screening for nonarteriitic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 3-8.

69. Nagy V, Takacs L, Steiber Z, et al. Thrombophilic screening in retinal artery occlusion patients. Clinical Ophthalmology 2008; 2: 557-561.

70. Noma H, Funatsu H, Yamasaki M. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of makular ödéma in branch retinal vein occlusion. Eye 2008; 22: 42-48.

71. Noma H, Funatsu H, Yamasaki M. Pathogenesis of makular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol, 2005; 140: 256-61.

72. O'Mahoney PR, Wong ОТ, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126: 692-9.

73. Paques M, Girmens JE Riviere E, et al. Dilation of the minor arterial circle of the iris preceding rubeosis iridis during retinal vein occlusion. Am J Ophthalmol 2004; 138: 1083-1086.

74. Parodi M, Bandello F Branch retinal vein occlusion: classification and treatment. Ophthalmologica 2009; 223: 298-305.

75. Pliegler Gy, editor. A thromboembolia kockázatának csökkentése és kezelése (Irányelv). Orvosi Hetilap 2009; 150: 335-2404.

76. Prager E Michels S, Kriechbaum K. Intravitreal bevacizumab (Avastin) for makular ödéma secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93: 452.

77. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis,visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-31.

78. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: An evidence-based systematic review. Ophthalmology 2010; 117: 1094-1101.

79. Sanborn GE, Magargal LE. Venous Occlusive Disease of the Retina. In Tasman W. Duane’ ophthalmology on dvd-rom. Baltimore: Chapter 15. Lippincott; 2009.

80. Scott IL), Ip MS, VanVeldhuisen PC, and SCORE Study Research Group Study: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with makular edema secondary to branch retinal vein occlusion:the SCORE study Report 6. Arch Ophthalmol 2009; 127: 1115.

81. Sekiryu T, Yamauchi T, Enaida H. Retina tomography after vitrectomy for makular edema of central retinal vein occlusion. Ophthalmic Surg Lasers 2000; 31: 198-202.

82. Shahid H, Hossain R Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90: 627-39.

83. Sinclair SH, Gragoudas ES. Prognosis for rubeosis iridis following central retinal vein occlusion. Br J Ophthalmo 1979; 63: 735-741.

84. Sofi E Marcucci R, Bolli R Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis 2008; 198: 223-7.

85. Spaide RE Chang LK, Klancnik JM. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.

86. Stewart MW. The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology. Mayo Clin Proc 2012; 87: 77-88.

87. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for makular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-82.

88. The Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, A randomized clinical trial. Arch Ophthalmol 1986; 104: 34-41.

89. The Central Vein Occlusion Study Group: A randozed clinical trial of early panretinal photocoagulation for ischaemic central vein occlusion. N report. Ophthalmology 1995; 102:1434-1444.

90. The Central Vein Occlusion Study Group: Evaluation of grid pattern photocoagulation for makular edema in central vein occluison. M report. Ophthalmology 1995; 102: 1425-1433.

91. The Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545.

92. The Royal College of Ophthalmologists: Interim Guidelines for Management of Retinal Vein Occlusion. 2010: www.rcophth.ac.uk.

93. Wong TY, Larsen EK, Klein R. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in CommunitiesS-Cardiovascular Health studies. Ophthalmology 2005; 112: 540-7.

94. Wong TY, Scott IU. Retinal-Vein Occlusion. N Engl J Med 2010; 363: 2135-2144.

95. Wroblewski JJ, Wells JA, Gonzales CR. Pegabtanib sodium for makular edema secondary to branch retinal vein occlusion. Am J Ophthalmol 2010; 149: 147-157.

96. Wu L, Arevalo J, Berrocal MH. Results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2010; 1002-11.

97. Zampros I, Praidou A, Brazitikos R et al. Antivascular Endothelial Growth Factor Agents for Neovascular Age-RelatedMakular Degeneration. Journal of Ophthalmology 2012. Article ID 319728, doi:10.1155/ 2012/ 319728.